Myogen Drops Heart Failure Agent Following Failed Phase III Studies
The oral PDE-3 inhibitor enoximone failed to show a significant benefit for any of three co-primary endpoints in two Phase III trials.
The oral PDE-3 inhibitor enoximone failed to show a significant benefit for any of three co-primary endpoints in two Phase III trials.